The Prostate Cancer Clinical Trials Consortium Selects WIRB-Copernicus
PCCTC will utilize its services for the review of its cancer research protocols and related study documents.
WIRB-Copernicus Group, a provider of regulatory and ethical review services and software to support clinical research, and the Prostate Cancer Clinical Trials Consortium (PCCTC), a multicenter clinical research organization specializing in cutting-edge prostate cancer research, announced PCCTC will utilize its services for the review of its cancer research protocols and related study documents. This is a significant change for PCCTC, which previously relied on its members’ local IRBs.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
